How many cycles before I know if it works?

Three. Trials measured change across three menstrual cycles, and effects build gradually.

Should I only take it in the second half of my cycle?

No. Trials used continuous daily dosing, which fits a mechanism based on ongoing pituitary signalling.

Which symptom responds best?

Cyclical breast tenderness has the most consistent signal, followed by irritability and mood symptoms.

Outcome

Moderate Evidence

Vitex (Chasteberry) for PMS Symptom Relief

Chasteberry is the best-supported option specifically for breast tenderness and premenstrual irritability.

Overview

Vitex agnus-castus, or chasteberry, is the most studied botanical for premenstrual syndrome and one of the few with pooled randomised data behind it. Trials consistently report improvement in the composite premenstrual symptom score, with breast tenderness and irritability among the most responsive individual symptoms.

The caveat is embedded in the meta-analyses themselves. Pooled effect sizes are large, but when the analysis is restricted to trials at low risk of bias the effect shrinks substantially, and heterogeneity across studies is high. Several trials were funded by extract manufacturers. The practical reading: chasteberry is a reasonable first-line option for mild to moderate PMS, especially where breast tenderness dominates, but the true effect is probably closer to modest than to the headline numbers.

Verdict

Likely effective

Multiple meta-analyses of randomised trials favour Vitex over placebo for overall premenstrual symptom scores. Effects attenuate in low-risk-of-bias trials and heterogeneity is high.

How It Works

Vitex constituents bind dopamine D2 receptors on lactotroph cells in the pituitary. Dopaminergic activity there suppresses prolactin release, and mild latent hyperprolactinaemia is one plausible driver of cyclical breast tenderness and luteal phase symptoms. Lowering prolactin is the best-supported mechanism for this pairing.

Secondary mechanisms are proposed but weaker. Diterpenes in the extract have been described as acting on opioid and oestrogen receptors, which could contribute to mood and pain effects, though this is largely preclinical. What Vitex does not do is act as a hormone. It does not supply oestrogen or progesterone; it nudges the pituitary signal upstream of them. That distinction matters for both expectations and interaction risk.

Primary target: Pituitary dopamine D2 receptors
Downstream effect: Reduced prolactin secretion
Most responsive symptom: Cyclical breast tenderness (mastalgia)
Not a hormone: Supplies no oestrogen or progesterone
Onset: Effects build across two to three cycles

Dosing & Protocol

Trial doses cluster around 20 to 40 mg daily of a standardised dried extract, taken once each morning and continuously rather than only in the luteal phase. Because the mechanism runs through pituitary signalling, dosing every day of the cycle is the pattern that was actually tested.

Context	Dose	Form	Timing
Common trial dose	20-40 mg daily	Standardised dried extract (e.g. Ze 440, BNO 1095)	Morning, continuous through the cycle
Breast tenderness focus	20 mg daily	Standardised extract	Morning
Tincture equivalent	1-2 ml daily	1:5 tincture	Morning
Assessment window	3 cycles	Any standardised form	Daily

1
Choose a standardised extract· Before starting
Trials used defined extracts, not generic berry powder. Look for a named extract or a stated standardisation.
2
Take 20-40 mg each morning· Daily
Continuous daily dosing, not luteal-phase-only.
3
Track symptoms prospectively· From cycle 1
Rate breast tenderness, irritability and bloating daily. Retrospective recall overstates both PMS and improvement.
4
Judge after three cycles· Cycle 3
Most trials measured change over three menstrual cycles. Stopping at one cycle is stopping too early.

Rule out PMDD first

Severe cyclical mood disturbance that disrupts work or relationships is premenstrual dysphoric disorder, which has its own evidence-based treatments. Chasteberry is not the right first move there.

Evidence

The evidence base is unusual in being almost entirely meta-analytic: several independent pooled analyses of overlapping randomised trials, all favouring Vitex, all flagging the same quality problems. Read the effect size and the risk-of-bias comment together.

Meta-analyses linked to this pairing.

The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis

Score: 9/10

2017

meta_analysis

n=1071

Verkaik S, Kamperman AM, van Westrhenen R +1 more

Trials with low risk of bias yielded substantially smaller effect sizes than weaker studies of Vitex agnus castus.

View source

Vitex agnus-castus for premenstrual syndrome: a systematic review and meta-analysis of randomised controlled trials

Score: 7/10

2017

meta_analysis

n=1300

Verkaik S, Kamperman AM, van Westrhenen R +1 more

Vitex extract produced a large reduction in premenstrual symptom scores versus placebo

View source

Best available evidence: Systematic reviews and meta-analyses of randomised placebo-controlled trials
Typical effect: Large pooled reduction in premenstrual symptom score; smaller in low-bias trials
Studied dose: 20-40 mg daily standardised extract
Time to effect: Two to three menstrual cycles
Main limitation: High heterogeneity and manufacturer funding across included trials

Safety

Adverse effects in trials were mild and comparable to placebo: nausea, headache, gastrointestinal upset and occasional acne. The meaningful cautions are contextual rather than toxicological, and they follow from the prolactin mechanism.

Cautions

Avoid in pregnancy and while breastfeeding

Avoid with hormone-sensitive cancers unless specialist-approved

Can alter cycle length in the first cycles

Mild nausea, headache or acne possible

Not appropriate for undiagnosed amenorrhoea

Interactions & Conflicts

Because Vitex works on dopamine signalling, its interactions are mostly with drugs that act on the same pathway in the opposite direction. It is also frequently combined with hormonal contraception, where the theoretical opposition is worth knowing even though clinical reports are scarce.

Interacts with	Severity	Mechanism	Action
Dopamine antagonists (antipsychotics, metoclopramide)	moderate	Opposing action at D2 receptors	Discuss with your prescriber before combining
Dopamine agonists (bromocriptine, cabergoline)	moderate	Additive prolactin suppression	Avoid stacking without specialist supervision
Combined hormonal contraception	low	Theoretical interference with hormonal regulation	Generally used together; report any cycle changes
Fertility treatment	moderate	Alters prolactin and cycle timing	Tell your fertility clinic before starting

References

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.